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Transcription factors (TFs) play a key role in determining the gene expression proﬁles of stem/
progenitor cells, and deﬁning their potential to differentiate into mature cell lineages. TF
interactions within gene-regulatory networks are vital to these processes, and dysregulation of
these networks by TF overexpression, deletion or abnormal gene fusions have been shown to
cause malignancy. While investigation of these processes remains a challenge, advances in
genome-wide technologies and growing interactions between laboratory and computational
science are starting to produce increasingly accurate network models. The haematopoietic system
provides an attractive experimental system to elucidate gene regulatory mechanisms, and allows
experimental investigation of both normal and dysregulated networks. In this review we examine
the principles of TF-controlled gene regulatory networks and the key experimental techniques
used to investigate them. We look in detail at examples of how these approaches can be used to
dissect out the regulatory mechanisms controlling normal haematopoiesis, as well as the
dysregulated networks associated with haematological malignancies.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY
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The haematopoietic system has long been at the forefront of
research into the processes of normal and abnormal cell differ-
entiation, both in foetal development and in the ongoing produc-
tion of mature cells in adult life [1,2]. Analysis of surface
expression markers and isolation of distinct populations by ﬂow
cytometry has enabled the precise immunophenotypic character-
isation of both developmental and mature forms of blood cells.
Despite ongoing reﬁnement, the “haematopoietic tree” outlining
the major haematopoietic developmental pathways is well-
deﬁned in general terms with at least 14 mature cell types
present in the normal adult, and a signiﬁcant progress has been
made into understanding the processes regulating these progres-
sions [2,3].
The key role of transcription factors (TFs) in regulating
haematopoietic cell fate has long been recognised. Many TFs
were originally identiﬁed following the observation of novel
transcripts resulting from chromosomal translocations in hae-
matological malignancies, for example Runx1 in the Runx1
(AML1)–ETO fusion protein of t(8;21) acute myeloid leukaemia
(AML) [4], Scl(Tal1) in t(1;14) T-cell acute lymphobla-
stic leukaemia (T-ALL) [5] and Lmo2 in t(11;14) T-ALL [6].
More recently, cellular reprogramming across haematopoietic
lineages using combinations of TFs [7] and induction of pluri-
potency [8] has reinforced the key roles TFs play in determin-
ing cell fate.
An early attempt to provide a conceptual framework for cell fate
decisions was made by Waddington, who conceived of an
irreversible process described in terms of balls rolling downhill
through bifurcating valleys which represented distinct maturing
lineages [9]. The ability to manipulate these processes, with cells
able to move between lineages under appropriate stimulation
[10,11], has suggested that a more plastic model more accurately
represents reality in vivo. Using concepts from the network
theory, Waddington's valleys can be replaced by “attractor states”
– relatively stable conditions representing the totality of
expressed genes at a given point, through which cells transit
during differentiation [12]. Control of gene expression occurs
through the combination of TFs, epigenetic regulators, and the
cis-regulatory elements within the genome with which they
interact (promoters, enhancers etc.) [13]. The totality of these
components may be considered a “gene regulatory network”, and
the inputs and outputs modelled as network motifs. Alon has
described these in detail, and shown that motifs such as coherent
and incoherent feed forward loops have demonstrable biological
counterparts [14]. An example from haematopoiesis is the posi-
tive feed-forward loop formed by the Scl complex and Mybcontrolling the gene expression programme of T-ALL cells, as
described below [15].
Just as normal haematopoiesis is determined by the effects of
gene regulatory networks on gene expression, disturbances of
these networks by mutations, deletions or oncogenic fusions of
TFs can lead to alternative attractor states, representing malig-
nant transformation. In the review below, we discuss experi-
mental and analytical techniques for investigating normal and
dysregulated gene regulatory networks in haematopoietic tis-
sue, and go on to describe examples of these from the recent
literature.Key experimental techniques in establishing TF
networks
Investigation into the roles of TFs in gene regulatory networks
requires the identiﬁcation of candidate TFs and their regulatory
elements within a given system, and then conﬁrmation of DNA
binding and its effect on gene expression and cell phenotype.
Interactions between multiple TFs may be suggested by the
analysis of parallel DNA-binding experiments, and biophysical
experiments can then identify individual components of TF-
complexes and the interactions between them. Final integration
of all the components and interactions increasingly requires
bioinformatic analyses and computational network modelling;
this can then be used iteratively to suggest new hypotheses for
subsequent experimental validation. A schema illustrating this
approach is shown in Fig. 1.Identiﬁcation of transcription factors
As noted above, initial identiﬁcation of many TFs resulted from
observed gene-fusions produced from chromosomal transloca-
tions in haematological malignancies [4–6]. Knockout studies
such as those on Scl in foetal development, can then determine
the relevance of a given TF in haematopoiesis [16,17].
Following the completion of the human genome project, it has
been possible to identify putative TFs by sequence analysis for
known DNA-binding motifs in coding regions, and subsequently
assess the expression of these transcript sequences in different
cell types. Dedicated online resources for the blood system,
including gene expression compendia such as Gene Expression
Commons [18], have further improved this process.
Identification of Transcription Factors (TFs)
Chromosomal translocations Knockout studies in fetal
development 
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Fig. 1 – A schema for the investigation of transcriptional networks in the haematopoietic system.
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A number of techniques may be used to establish the DNA-
binding capability of a given TF, for example electrophoretic
mobility shift assays (EMSA) [19,20] and DNase footprinting
assays [21]. The current “workhorse” of TF–DNA binding however
is chromatin immunoprecipitation (ChIP), which produces a pool
of DNA fragments enriched for the binding of the TF under
investigation. Individual genomic regions can be interrogated
using quantitative PCR (qPCR), but new sequencing technologies
now allow global assessment of entire genomes using ChIP-Seq
(ChIP followed by whole genome massively parallel DNA sequen-
cing). Mapping of individual sequencing reads onto a reference
genome allows an unbiased assessment of genome-wide bindingevents, with high resolution, low noise levels, and a high dynamic
range. This technology represents a signiﬁcant improvement over
ChIP followed by array based hybridisation (ChIP-chip) [22,23].
As with gene expression [18,24] and epigenomic data [25], there
are ongoing efforts to generate online resources that compile
multiple ChIP-Seq studies generated by the haematopoiesis
research community [26,27].
Physical interactions between distal cis-acting regulatory ele-
ments and speciﬁc gene promoters can be mapped using Chro-
mosome Conformation Capture (3C) methods and more recent
variants such as 4C, 5C and Capture-C [28–30]. These techniques
involve digestion and re-ligation of ﬁxed chromatin followed by
quantiﬁcation of ligation junctions, which reﬂects the frequencies
of interaction. Distal regulatory elements are commonly found
many kilobases – and sometimes more than a megabase – away
E X P E R I M E N T A L C E L L R E S E A R C H 3 2 9 ( 2 0 1 4 ) 2 5 5 – 2 6 4258from the promoters they interact with, with one or more genes
in-between the regulatory element and its actual target promoter.
Chromosome Conformation Capture techniques have the poten-
tial therefore to address potential ambiguities in assigning distal
elements to their cognate target promoters, and thus help reﬁne
our understanding of complex networks. Limitations persist
however, in particular distinguishing genuine interactions from
background noise, and ensuring that coverage is comprehensive
enough to cover all relevant genomic interactions.Functional relevance of TF–DNA binding
Once binding sites have been identiﬁed, their functional relevance
as cis-regulatory elements can be assessed by luciferase assays
[31–34], and their tissue-speciﬁc in vivo activity by reporter
assays in transgenic mouse embryos [35–37]. Loss of function
analysis through deletion of regulatory sequences in their endo-
genous genomic context, has been very cumbersome until
recently. However, novel gene-targeting technologies such as
TAL Effectors and CRISPR are now showing promise in assessing
the effects of targeting speciﬁc regulatory elements in a more
efﬁcient manner [38].
TFs can either enhance or inhibit transcriptional activity, with
many TFs able to act both as activators and repressors depending
on the speciﬁc gene regulatory context (co-bound TFs, cell type,
isoform, post-translational regulation etc.). The effect of a TF on a
given gene regulatory sequence may be assessed by performing
reporter assays, following the targeted mutation of speciﬁc
binding sites [39,40].Effect on target genes
Since the primary effect of TF activity is on gene expression,
regulatory effects can also be evaluated on a genome-wide scale
using expression arrays or RNA-Seq, following either overexpres-
sion or knock-down of a given TF. However, expression analyses
cannot pinpoint the speciﬁc regulatory elements mediating
transcriptional regulation, and indeed will also report expression
changes due to indirect regulation. Recent advances now allow
assessment of gene expression in individual cells, and these
techniques have the potential to examine effects within small
populations, such as those seen at the earliest stages of blood
stem cell differentiation [41,42]. Our group has used these
techniques to conﬁrm known interactions at the single cell level,
and also identiﬁed new networks with previously unknown
interactions, such as that between Gata2, Gﬁ1 and Gﬁ1b [43].Interactions between transcription factors
Interactions between different TFs may be suggested by genomic
co-localisation on parallel ChIP-Seq experiments. Physical inter-
actions can be established by co-immunoprecipitation (CoIP)
assays, or if multiple factors are bound within a complex, more
elaborate techniques such as high-stringency puriﬁcations [44],
or SILAC [45], followed by mass-spectrometry and immunoblot-
ting to establish the constituent factors. Yeast 2 hybrid assayshave also been employed to conﬁrm the functional relationships
between TFs and cooperating proteins [46].Data integration and modelling
Translating experimental data into network models can be done
using broadly “bottom-up” or “top-down” approaches. “Bottom-
up” studies use small sets of TFs and regulatory elements to build
up a detailed understanding of a given network. For example, the
Scl–Gata2–Fli1 triad discussed below was initially investigated
with detailed experiments, that were later complemented by
computational modelling approaches [47–50]. The increasing use
of genome-wide datasets lends itself to “top-down” approaches,
where advanced statistical analysis and computational modelling
are used to infer networks, which can then be further investigated
with speciﬁc, directed experimental work. Examples of this
approach include the discovery of a “heptad” of seven co-
binding TFs emerging from parallel ChIP-Seq experiments dis-
cussed below [37], and the central role played by c-Myc in B cells
derived from comprehensive analysis of gene expression array
and ChIP-chip data [51].
Integrated analysis using data generated by different research
groups is also becoming increasingly feasible. The ENCODE project
achieved this using a coordinated approach with pre-set experi-
mental standards arranged between a number of groups [52].
More recently, post-hoc curation of existing datasets have yielded
large tissue-speciﬁc collections [27,53].Reconstruction of regulatory networks – normal
haematopoiesis
Using the experimental and analytical techniques described above,
several different gene regulatory networks have been delineated
within the haematopoietic system. In addition to the examples
discussed below, other groups have described networks in T-reg
differentiation and function [54], B-cell lineage commitment
[55,56], and the Pu.1/Notch interaction determining T-cell or
myeloid lineage fate [57].Pu.1/Gata1 antagonism
An example of mutual antagonism between TFs determining
lineage commitment is the interaction between Pu.1 and Gata1,
the study of which illustrates the beneﬁcial interactions of
both experimental and analytical work (Fig. 2a). Pu.1 expres-
sion in the erythroid–myeloid lineage causes monocytic differ-
entiation, while Gata1 causes erythroid and megakaryocytic
differentiation [58]. Both TFs positively auto-regulate their
own expression [59,60], and Gata1 has been shown to reduce
Pu.1 expression by binding at its regulatory regions [61], as
well as directly inhibiting Pu.1 protein activity at the Ets-
domain [62]. Wontakal et al. used mathematical modelling to
demonstrate that the combination of mutual inhibition, and
repression of opposing downstream targets maximises the
antagonistic interaction between the two TFs [63].
An alternative modelling approach to this system suggested the
requirement for a previously unidentiﬁed third element to
Gata1 Pu.1
Erythrocyte /
Megakaryocyte
Monocyte
Fli1 Gata2
Scl
Fig. 2 – Modelling transcriptional regulatory networks in haematopoiesis. Activating interactions are shown as blue arrows,
repressing interactions in red. (a) Cross-antagonism between Gata1 and Pu.1 determining erythroid–myeloid lineage fate.
(b) The HSC triad composed of Fli1, Gata2, and Scl. Positive auto-regulatory activity between the three constituent factors
maintains a bistable network. (c) Regulatory network based on ten TF ChIPSeq, illustrating interactions between constituent
members of Scl/Lyl1/Lmo2/Gata2/Runx1/Erg/Fli1 heptad. The predicted–and subsequently validated–negative regulation of Fli1 by
Gata1 is shown by a dashed line.
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feature for robust lineage determination [64]. Subsequent dis-
covery of the role of Tif1g in differentially controlling the levels of
Gata1 and Pu.1 in HSCs, makes this is an attractive candidate for
this role [65].
This model has recently been questioned by single cell
expression data from our group, which showed that while the
majority of progenitor cells expressed only either Pu.1 or Gata1
(consistent with mutual inhibition), a small number expressed
both TFs with apparently positively correlated levels (not
consistent with mutual inhibition). This illustrates the power
of single cell analysis to shed new light on regulatory networks,
something that is likely to become more prominent in the
future [43].Scl/Gata2/Fli1 triad
An example of a triad of cross-regulatory TFs is provided by
the interactions of Scl, Gata2 and Fli1 in foetal haematopoiesis
(Fig. 2b). Initial studies on the Sclþ19 enhancer region
revealed binding by Fli1 and Gata2 via Ets and Gata motifs
respectively [47]. Computational genome-wide searches sub-
sequently revealed the same cluster of binding-motifs at the
Fli1þ12 [48] and Gata2–3 enhancer regions, with evidence of
haematopoietic-localised activity demonstrated by transgenic
mouse embryo assays in each case. Positive regulatory activity
between each of the three TFs was shown by targeted muta-
tion of DNA-binding sites followed by luciferase assays [49].
Subsequent modelling of this co-regulatory system revealed a
network that is both bistable (either “all on” or “all off”), and
characterised by low-pass ﬁltering (i.e. relatively insensitive tolow level perturbations from other factors such as Notch and
Bmp4) [50].Scl/Lyl1/Lmo2/Gata2/Runx1/Erg/Fli1 heptad
The ability to integrate data from multiple TF ChIP-Seq experi-
ments, has led to new insights into complementary binding
patterns. An example is the ten TFs tested in a murine multipotent
progenitor cell line, in which a statistically overrepresented
binding pattern identiﬁed a “heptad” of combinatorial binding
by seven TFs (Scl, Lyl1, Lmo2, Gata2, Runx1, Erg and Fli1). The
absence of binding motifs in a signiﬁcant proportion of TF-bound
regions for some of the factors suggested protein–protein inter-
actions, which were conﬁrmed by CoIP experiments (e.g. Runx1
and Scl) [37]. Subsequent research has conﬁrmed a similar
binding pattern of the TF “heptad” in human primary CD34þ
cells [66]. Boolean modelling of the original dataset predicted
patterns of gene expression which matched those of known
haematological cell states. Looking in detail at the network sug-
gested a “missing link” in the interactions determining erythroid
differentiation, which was hypothesised to be negative regulation of
Fli1 by Gata1. Subsequent experiments validated the ability of Gata1
to negatively regulate expression of Fli1 by binding at its enhancer,
conﬁrming the predicted interaction and supporting the value of
this type of network analysis (Fig. 2c) [67].
A further study used a gene expression signature based on the
heptad binding pattern to stratify human AML expression data-
sets, where interestingly it was identiﬁed as an independent risk
factor for poor prognosis [68]. This suggests that the net effect of
the combinatorial binding of these seven TFs may be to maintain a
stem cell “attractor state” in leukaemic cells, with a direct impact
on clinical outcome.
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Given the tightly controlled interactions between TFs in deter-
mining and maintaining normal haematopoiesis, it is unsurprising
that disturbances to these systems can lead to dysregulation, and
ultimately the abnormal proliferation of cells characterising
haematological malignancies. Three well-described examples are
detailed below, but a number of other studies demonstrating TF
dysregulation in haematopoietic networks have been performed,
for example TLX1 and TLX3 fusion oncoproteins down-regulating
the Runx1 promoter in T-ALL [69], Pu.1 and Irf9 antagonism of
miR-342 expression following ATRA exposure in APML cells [70],
and CEBPβ binding to Irf4, Xbp1 and Blimp1 regulatory sites in
myeloma cell lines [71].Scl in T-ALL
Sanda et al., [15] investigated the regulatory network of Scl (Tal1),
a TF that is overexpressed in a signiﬁcant proportion of T-ALL
cases [72]. Scl ChIP-Seq in T-ALL cell lines and primagrafts showed
consistent binding patterns with E-box, Gata, Runx and Ets motifs
identiﬁed within 200 bp of the Scl binding, and frequent regions
of overlap between Scl and the TFs E2A, Heb, Lmo1, Lmo2, Gata3
and Runx1. Interdependence between Scl, Runx1 and Gata3 was
suggested by the presence of reciprocal binding at regulatory
elements on loci by members of the complex in T-ALL cells, and
reciprocal shRNA knockdown of each of the triad members caused
down-regulation of the others, as well as inhibiting cell growth
and promoting apoptosis.
Principal-component analysis of gene expression in 75 primary
T-ALL and seven normal samples using the set of 238 genes bound
by Scl and signiﬁcantly downregulated after Scl knockdown,
clearly distinguished the Scl overexpressing cases, conﬁrming
the pathological and clinical relevance of this network. Finally,
the oncogene Myb – previously described to be overexpressed in
T-ALL [73,74] – was downregulated by knockdown of Scl, Runx1
and Gata3, and conversely knockdown of Myb led to down-
regulation of many Scl targets. This pattern of Myb regulation by
Scl and concurrent regulation of Scl targets by Myb, suggests a
role in reinforcing the regulatory circuit in a feed-forward loop,
pathologically maintaining an aberrant attractor state in Scl-
driven T-ALL. Other small subcircuits with possible relevance for
T-ALL have been discovered by analysing transcriptional control
mechanisms of Lmo2 [75,76].Runx1–ETO in t(8;21) AML
The role of Runx1–ETO (commonly referred to as AML1–ETO) in t
(8;21) AML is well recognised [77], where it is generally thought
to act as transcriptional repressor through recruitment of NCOR
and HDAC proteins [78–80] and reduction of histone acetylation
[81]. Sun et al. used a variety of techniques to investigate the
components of the Runx1–ETO containing TF complex (AETFC),
and their roles in leukemogenesis [44]. AETFC was isolated using
a high-speciﬁcity anti-ETO antibody followed by high-stringency
buffer puriﬁcation, and the components of the complex were then
identiﬁed by a combination of SDS-PAGE, immunoblot and mass-spectroscopy. A number of TFs were identiﬁed within the com-
plex, including CBFβ, Lyl1, Lmo2, Ldb1 and the E proteins HEB and
E2A. The interactions between them were investigated by CoIP,
and ChIP-Seq conﬁrmed co-localisation at a number of binding
sites. Knockdown of individual AETFC components (especially E2A
and HEB) in Runx1–ETO9a-transformed splenic murine cells
reduced the degree of leukemogenicity, suggesting a key role
for the individual components of the complex.
Subsequent X-ray crystallographic analysis identiﬁed a novel
interaction at the NHR2 domain of Runx1–ETO and a binding site
(N2B) on the E protein HEB. Disruption of this interaction reduced
cell-initiating potential in in vitro models, as well as reducing
leukemogenicity and improving survival in a mouse model. This
study illustrates the power of combining genomic technologies,
with biophysical and in vivo experiments to delineate the speciﬁc
physical structure underlying a TF interaction, and assessing the
effects of its manipulation on disease outcomes in animal models.CM in AML inv16
Another well-characterised fusion oncogene is CBFβ-MYH11 (CM)
formed by the chromosomal translocation inv(16), which is clini-
cally characterised by the AML subtype M4Eo (eosinophilic).
CM combines the DNA-binding stabilisation CBFβ subunit of the
core binding factor (CBF), with the smooth muscle myosin heavy
chain MYH11. The oncogenic fusion protein has been hypothesised
to act as a dominant negative mutation affecting normal Runx1
transcriptional function [82,83]. Mandoli et al., [45] performed
ChIP-Seq in the inv16 cell line ME1, using antibodies against each
of the two CM fusion partners as well as for Runx1 and Scl. CM
binding sites were all co-localised with Runx1 reinforcing the
suggestion that the CM-binding is Runx1-dependent. However in
contrast to the overall Runx-binding, the majority of CM binding
events were at promoter sites, indicating that additional factors
contribute in guiding CM to promoter regions.
Using a proteomic approach, the authors were able to identify
co-binding proteins, including various TBP-associated factors
(TAFs) of which TAF7 was conﬁrmed to interact with CM by CoIP.
ChIP for TBP and RNAPII (proteins that from a stable complex with
TAFs in a pre-initiation complex) showed co-localisation, and
reChIP experiments conﬁrmed CM interaction with these basal
transcriptional activators. Further TF ChIP-Seq showed other TFs
(e.g. Elf1, Fli1, Pu.1, Erg) co-localised with CM. CM binding was
associated with increased acetylation and altered gene expres-
sion, with both increases and decreases in transcription seen at
different loci, in contrast to the purely repressive function of CM
previously reported [83,84]. Potentially relevant to the leukaemo-
genic function of CM was the observation that a proportion of
those aberrantly regulated genes are involved in self-renewal
pathways. These experiments therefore point to the CM oncopro-
tein subverting the normal binding activity of Runx1 and other
cooperating TFs, to alter the overall transcriptional status of the
cell moving it into a leukaemic phenotype.Conclusions
The role of TFs in controlling haematopoiesis has long been
recognised, but we are now increasingly able to understand
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fate, and conversely how speciﬁc network perturbations can lead
to malignant phenotypes. Two factors in particular have led to
this greater understanding: innovation in genomic technologies,
and increased interactions between laboratory and computational
science.
ChIP-Seq has been key in allowing the interrogation of TF-
binding events on a genome-wide basis at an increasingly
affordable price, and the effects on gene expression changes can
be assessed by expression arrays or RNA-Seq. Cell number
remains a limiting factor for ChIP however, with 5000–100,000
cells the lowest numbers reported for a TF-ChIP, even with
additional ampliﬁcation steps used prior to sequencing [85,86].
This is in contrast to advances in transcriptomic technology,
where changes in gene expression can now be analysed at a
single cell level, providing major insights in heterogeneous and
rare cell populations [41,87].
The volume of data generated by these new types of experi-
ments requires analysis beyond the remit of most laboratory-
based scientists, and has led to increasing interactions with
computational scientists for analysis and network modelling.
These models can be used to direct laboratory experiments,
which in turn can reﬁne the models in a “virtuous circle” of
hypothesis generation, experimental testing and data analysis.
As demonstrated in the examples above, we believe that this
approach is ideally suited to the investigation of complex biolo-
gical systems such as the gene regulatory networks that deter-
mine cell fate. The next few years should see further advances in
our understanding of the control of cell differentiation both in
haematopoiesis and other ﬁelds, and provide further insights into
the mechanisms of oncogenesis.Acknowledgments
Research in the Göttgens laboratory is supported by the Leukae-
mia and Lymphoma Research, the MRC, BBSRC, CRUK, Leukemia
and Lymphoma Society, NIHR Cambridge Biomedical Research
Centre and core infrastructure support by the Wellcome Trust to
the Wellcome Trust and MRC Cambridge Stem Cell Institute and
CIMR. JIS is supported by CRUK and the Raymond and Beverly
Sackler Foundation.
The network diagram in Fig. 1(c) and incorporated into Fig. 2 is
reproduced from Bonzanni et al. Hard-wired heterogeneity in
blood stem cells revealed using a dynamic regulatory network
model. Bioinformatics. 2013; 29: i80-8 by permission of Oxford
University Press.
Components of Fig. 2 are reproduced with permission from the
UCSC Genome Browser http://www.genome.ucsc.edu, and Sun
et al. A Stable Transcription Factor Complex Nucleated by Oligo
meric AML1–ETO Controls Leukaemogenesis. Nature 2013; 500:
93–7 by permission from Macmillan Publishers Ltd.r e f e r e n c e s
[1] S.H. Orkin, L.I. Zon, Hematopoiesis: an evolving paradigm for
stem cell biology, Cell 132 (2008) 631–644.
[2] H. Ema, Y. Morita, T. Suda, Heterogeneity and hierarchy of
hematopoietic stem cells, Exp. Hematol. 42 (74–82) (2014) e2.[3] J. Schütte, V. Moignard, B. Göttgens, Establishing the stem cell
state: insights from regulatory network analysis of blood stem
cell development, Wiley Interdiscip. Rev.: Syst. Biol. Med. 4
(2012) 285–295.
[4] H. Miyoshi, K. Shimizu, T. Kozu, N. Maseki, Y. Kaneko, M. Ohki,
t(8;21) Breakpoints on chromosome 21 in acute myeloid leuke-
mia are clustered within a limited region of a single gene, AML1,
Proc. Natl. Acad. Sci. USA 88 (1991) 10431–10434.
[5] C.G. Begley, P.D. Aplan, M.P. Davey, K. Nakahara, K. Tchorz, J.
Kurtzberg, M.S. Hershﬁeld, B.F. Haynes, D.I. Cohen, T.A. Wald-
mann, Chromosomal translocation in a human leukemic stem-
cell line disrupts the T-cell antigen receptor delta-chain diversity
region and results in a previously unreported fusion transcript,
Proc. Natl. Acad. Sci. USA 86 (1989) 2031–2035.
[6] T. Boehm, L. Foroni, Y. Kaneko, M.F. Perutz, T.H. Rabbitts,
The rhombotin family of cysteine-rich LIM-domain oncogenes:
distinct members are involved in T-cell translocations to human
chromosomes 11p15 and 11p13, Proc. Natl. Acad. Sci. USA 88
(1991) 4367–4371.
[7] T. Graf, T. Enver, Forcing cells to change lineages, Nature 462
(2009) 587–594.
[8] K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells
from mouse embryonic and adult ﬁbroblast cultures by deﬁned
factors, Cell 126 (2006) 663–676.
[9] C.H. Waddington, The Strategy of the Genes: A Discussion of
Some Aspects of Theoretical Biology, Allen & Unwin262.
[10] M. Gering, Y. Yamada, T.H. Rabbitts, R.K. Patient, Lmo2 and Scl/
Tal1 convert non-axial mesoderm into haemangioblasts which
differentiate into endothelial cells in the absence of Gata1,
Development 130 (2003) 6187–6199.
[11] C. Heyworth, S. Pearson, G. May, T. Enver, Transcription factor-
mediated lineage switching reveals plasticity in primary com-
mitted progenitor cells, EMBO J. 21 (2002) 3770–3781.
[12] T. Enver, M. Pera, C. Peterson, P.W. Andrews, Stem cell states,
fates, and the rules of attraction, Cell Stem Cell 4 (2009) 387–397.
[13] E.H. Davidson, Network design principles from the sea urchin
embryo, Curr. Opin. Genet. Dev. 19 (2009) 535–540.
[14] U. Alon, Network motifs: theory and experimental approaches,
Nat. Rev. Genet. 8 (2007) 450–461.
[15] T. Sanda, L.N. Lawton, M.I. Barrasa, Z.P. Fan, H. Kohlhammer,
A. Gutierrez, W. Ma, J. Tatarek, Y. Ahn, M.A. Kelliher, C.H.M.
Jamieson, L.M. Staudt, R.A. Young, A.T. Look, Core transcriptional
regulatory circuit controlled by the TAL1 complex in human T cell
acute lymphoblastic leukemia, Cancer Cell 22 (2012) 209–221.
[16] L. Robb, I. Lyons, R. Li, L. Hartley, F. Köntgen, R.P. Harvey,
D. Metcalf, C.G. Begley, Absence of yolk sac hematopoiesis from
mice with a targeted disruption of the scl gene, Proc. Natl. Acad.
Sci. USA 92 (1995) 7075–7079.
[17] R.A. Shivdasani, E.L. Mayer, S.H. Orkin, Absence of blood forma-
tion in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL,
Nature 373 (1995) 432–434.
[18] J. Seita, D. Sahoo, D.J. Rossi, D. Bhattacharya, T. Serwold,
M.A. Inlay, L.I.R. Ehrlich, J.W. Fathman, D.L. Dill, I.L. Weissman,
Gene Expression Commons: an open platform for absolute gene
expression proﬁling, PloS One 7 (2012) e40321.
[19] M.M. Garner, A. Revzin, A gel electrophoresis method for
quantifying the binding of proteins to speciﬁc DNA regions:
application to components of the Escherichia coli lactose operon
regulatory system, Nucl. Acids Res. 9 (1981) 3047–3060.
[20] M. Fried, D.M. Crothers, Equilibria and kinetics of lac repressor-
operator interactions by polyacrylamide gel electrophoresis,
Nucl. Acids Res. 9 (1981) 6505–6525.
[21] D.J. Galas, A. Schmitz, DNAse footprinting: a simple method for
the detection of protein-DNA binding speciﬁcity, Nucl. Acids Res.
5 (1978) 3157–3170.
[22] P.J. Park, ChIP-seq: advantages and challenges of a maturing
technology, Nat. Rev. Genet. 10 (2009) 669–680.
E X P E R I M E N T A L C E L L R E S E A R C H 3 2 9 ( 2 0 1 4 ) 2 5 5 – 2 6 4262[23] T.S. Furey, ChIP-seq and beyond: new and improved methodol-
ogies to detect and characterize protein-DNA interactions, Nat.
Rev. Genet. 13 (2012) 840–852.
[24] R. Edgar, M. Domrachev, A.E. Lash, Gene expression omnibus:
NCBI gene expression and hybridization array data repository,
Nucl. Acids Res. 30 (2002) 207–210.
[25] D. Adams, L. Altucci, S.E. Antonarakis, J. Ballesteros, S. Beck,
A. Bird, C. Bock, B. Boehm, E. Campo, A. Caricasole, F. Dahl, E.T.
Dermitzakis, T. Enver, M. Esteller, X. Estivill, A. Ferguson-Smith, J.
Fitzgibbon, P. Flicek, C. Giehl, T. Graf, F. Grosveld, R. Guigo, I. Gut,
K. Helin, J. Jarvius, R. Küppers, H. Lehrach, T. Lengauer,
Å. Lernmark, D. Leslie, et al., BLUEPRINT to decode the epigenetic
signature written in blood, Nat. Biotechnol. 30 (2012) 224–226.
[26] R. Hannah, A. Joshi, N.K. Wilson, S. Kinston, B. Göttgens, A
compendium of genome-wide hematopoietic transcription factor
maps supports the identiﬁcation of gene regulatory control
mechanisms, Exp. Hematol. 39 (2011) 531–541.
[27] D. Ruau, F.S.L. Ng, N.K. Wilson, R. Hannah, E. Diamanti, P.
Lombard, S. Woodhouse, B. Göttgens, Building an ENCODE-style
data compendium on a shoestring, Nat. Methods 10 (2013) 926.
[28] J.-M. Belton, R.P. McCord, J.H. Gibcus, N. Naumova, Y. Zhan, J.
Dekker, Hi-C: a comprehensive technique to capture the con-
formation of genomes, Methods 58 (2012) 268–276.
[29] A. Gavrilov, E. Eivazova, I. Priozhkova, M. Lipinski, S. Razin,
Y. Vassetzky, Chromosome conformation capture (from 3C to 5C)
and its ChIP-based modiﬁcation, Methods Mol. Biol. 567 (2009)
171–188.
[30] J.R. Hughes, N. Roberts, S. McGowan, D. Hay, E. Giannoulatou,
M. Lynch, M. De Gobbi, S. Taylor, R. Gibbons, D.R. Higgs, Analysis
of hundreds of cis-regulatory landscapes at high resolution in a
single, high-throughput experiment, Nat. Genet. 46 (2014) 205–
212.
[31] J.-R. Landry, S. Kinston, K. Knezevic, I.J. Donaldson, A.R. Green,
B. Göttgens, Fli1, Elf1, and Ets1 regulate the proximal promoter of
the LMO2 gene in endothelial cells, Blood 106 (2005) 2680–2687.
[32] J.E. Pimanda, W.Y.I. Chan, I.J. Donaldson, M. Bowen, A.R. Green,
B. Göttgens, Endoglin expression in the endothelium is regulated
by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb
enhancer, Blood 107 (2006) 4737–4745.
[33] E.O. Bockamp, F. McLaughlin, B. Göttgens, A.M. Murrell,
A.G. Elefanty, A.R. Green, Distinct mechanisms direct SCL/tal-1
expression in erythroid cells and CD34 positive primitive mye-
loid cells, J. Biol. Chem. 272 (1997) 8781–8790.
[34] E.O. Bockamp, J.L. Fordham, B. Göttgens, A.M. Murrell, M.J.
Sanchez, A.R. Green, Transcriptional regulation of the stem cell
leukemia gene by PU.1 and Elf-1, J. Biol. Chem. 273 (1998)
29032–29042.
[35] E. Delabesse, S. Ogilvy, M.A. Chapman, S.G. Piltz, B. Gottgens,
A.R. Green, Transcriptional regulation of the SCL locus: identiﬁ-
cation of an enhancer that targets the primitive erythroid lineage
in vivo, Mol. Cell. Biol. 25 (2005) 5215–5225.
[36] J.-R. Landry, N. Bonadies, S. Kinston, K. Knezevic, N.K. Wilson, S.
H. Oram, M. Janes, S. Piltz, M. Hammett, J. Carter, T. Hamilton, I.J.
Donaldson, G. Lacaud, J. Frampton, G. Follows, V. Kouskoff,
B. Göttgens, Expression of the leukemia oncogene Lmo2 is
controlled by an array of tissue-speciﬁc elements dispersed over
100 kb and bound by Tal1/Lmo2, Ets, and Gata factors, Blood 113
(2009) 5783–5792.
[37] N.K. Wilson, S.D. Foster, X. Wang, K. Knezevic, J. Schütte,
P. Kaimakis, P.M. Chilarska, S. Kinston, W.H. Ouwehand,
E. Dzierzak, J.E. Pimanda, De Bruijn MFTR, B. Göttgens, Combi-
natorial transcriptional control in blood stem/progenitor cells:
genome-wide analysis of ten major transcriptional regulators,
Cell Stem Cell 7 (2010) 532–544.
[38] S. Gröschel, M.A. Sanders, R. Hoogenboezem, E. De Wit, B.A.M.
Bouwman, C. Erpelinck, V.H.J. Van der Velden, M. Havermans,
R. Avellino, K. Van Lom, E.J. Rombouts, M. Van Duin, K. Döhner,
H.B. Beverloo, J.E. Bradner, H. Döhner, B. Löwenberg, P.J.M. Valk,E.M.J. Bindels, W. De Laat, R. Delwel, A Single oncogenic
enhancer rearrangement causes concomitant evi1 and gata2
deregulation in leukemia, Cell 157 (2014) 369–381.
[39] S. Ogilvy, R. Ferreira, S.G. Piltz, J.M. Bowen, B. Göttgens,
A.R. Green, The SCL þ40 enhancer targets the midbrain together
with primitive and deﬁnitive hematopoiesis and is regulated by
SCL and GATA proteins, Mol. Cell. Biol. 27 (2007) 7206–7219.
[40] J.E. Pimanda, W.Y.I. Chan, N.K. Wilson, A.M. Smith, S. Kinston,
K. Knezevic, M.E. Janes, J.-R. Landry, A. Kolb-Kokocinski,
J. Frampton, D. Tannahill, K. Ottersbach, G.A. Follows, G. Lacaud,
V. Kouskoff, B. Göttgens, Endoglin expression in blood and
endothelium is differentially regulated by modular assembly of
the Ets/Gata hemangioblast code, Blood 112 (2008) 4512–4522.
[41] V. Moignard, B. Göttgens, Transcriptional mechanisms of cell fate
decisions revealed by single cell expression proﬁling, BioEssays:
News Rev. Mol. Cell. Dev. Biol. 36 (2014) 419–426.
[42] T. Kouno, M. De Hoon, J.C. Mar, Y. Tomaru, M. Kawano,
P. Carninci, H. Suzuki, Y. Hayashizaki, J.W. Shin, Temporal
dynamics and transcriptional control using single-cell gene
expression analysis, Genome Biol. 14 (2013) R118.
[43] V. Moignard, I.C. Macaulay, G. Swiers, F. Buettner, J. Schütte,
F.J. Calero-Nieto, S. Kinston, A. Joshi, R. Hannah, F.J. Theis,
S.E. Jacobsen, M.F. De Bruijn, B. Göttgens, Characterization of
transcriptional networks in blood stem and progenitor cells
using high-throughput single-cell gene expression analysis, Nat.
Cell Biol. 15 (2013) 363–372.
[44] X.-J. Sun, Z. Wang, L. Wang, Y. Jiang, N. Kost, T.D. Soong, W.-Y.
Chen, Z. Tang, T. Nakadai, O. Elemento, W. Fischle, A. Melnick, D.J.
Patel, S.D. Nimer, R.G. Roeder, A stable transcription factor
complex nucleated by oligomeric AML1-ETO controls leukae-
mogenesis, Nature 500 (2013) 93–97.
[45] A. Mandoli, A.A. Singh, Jansen PWTC, A.T.J. Wierenga, H. Riahi,
G. Franci, K. Prange, S. Saeed, E. Vellenga, M. Vermeulen,
H.G. Stunnenberg, J.H.A. Martens, CBFB-MYH11/RUNX1 together
with a compendium of hematopoietic regulators, chromatin
modiﬁers and basal transcription factors occupies self-renewal
genes in inv(16) acute myeloid leukemia, Leukemia 28 (2014)
770–778.
[46] E.A. Bard-Chapeau, J. Gunaratne, P. Kumar, B.Q. Chua, J. Muller,
F.A. Bard, W. Blackstock, N.G. Copeland, N.A. Jenkins, EVI1
oncoprotein interacts with a large and complex network of
proteins and integrates signals through protein phosphorylation,
Proc. Natl. Acad. Sci. USA 110 (2013) E2885–E2894.
[47] B. Göttgens, A. Nastos, S. Kinston, S. Piltz, E.C.M. Delabesse,
M. Stanley, M.-J. Sanchez, A. Ciau-Uitz, R. Patient, A.R. Green,
Establishing the transcriptional programme for blood: the SCL
stem cell enhancer is regulated by a multiprotein complex
containing Ets and GATA factors, EMBO J. 21 (2002) 3039–3050.
[48] I.J. Donaldson, M. Chapman, S. Kinston, J.R. Landry, K. Knezevic,
S. Piltz, N. Buckley, A.R. Green, B. Göttgens, Genome-wide
identiﬁcation of cis-regulatory sequences controlling blood and
endothelial development, Hum. Mol. Genet. 14 (2005) 595–601.
[49] J.E. Pimanda, K. Ottersbach, K. Knezevic, S. Kinston, W.Y.I. Chan,
N.K. Wilson, J.-R. Landry, A.D. Wood, A. Kolb-Kokocinski,
A.R. Green, D. Tannahill, G. Lacaud, V. Kouskoff, B. Göttgens,
Gata2, Fli1, and Scl form a recursively wired gene-regulatory
circuit during early hematopoietic development, Proc. Natl. Acad.
Sci. USA 104 (2007) 17692–17697.
[50] J. Narula, A.M. Smith, B. Gottgens, O.A. Igoshin, Modeling reveals
bistability and low-pass ﬁltering in the network module determining
blood stem cell fate, PLoS Comput. Biol. 6 (2010) e1000771.
[51] K. Basso, A.A. Margolin, G. Stolovitzky, U. Klein, R. Dalla-Favera,
A. Califano, Reverse engineering of regulatory networks in
human B cells, Nat. Genet. 37 (2005) 382–390.
[52] B.E. Bernstein, E. Birney, I. Dunham, E.D. Green, C. Gunter,
M. Snyder, An integrated encyclopedia of DNA elements in the
human genome, Nature 489 (2012) 57–74.
E X P E R I M E N T A L C E L L R E S E A R C H 3 2 9 ( 2 0 1 4 ) 2 5 5 – 2 6 4 263[53] D. Chacon, D. Beck, D. Perera, J.W.H. Wong, J.E. Pimanda, Blood-
ChIP: a database of comparative genome-wide transcription
factor binding proﬁles in human blood cells, Nucl. Acids Res. 42
(2014) D172–D177.
[54] D. Rudra, P. deRoos, A. Chaudhry, R.E. Niec, A. Arvey,
R.M. Samstein, C. Leslie, S.A. Shaffer, D.R. Goodlett, A.Y.
Rudensky, Transcription factor Foxp3 and its protein partners
form a complex regulatory network, Nat. Immunol. 13 (2012)
1010–1019.
[55] S. Zandi, R. Mansson, P. Tsapogas, J. Zetterblad, D. Bryder,
M. Sigvardsson, EBF1 is essential for B-lineage priming and
establishment of a transcription factor network in common
lymphoid progenitors, J. Immunol. 181 (2008) 3364–3372.
[56] Y.C. Lin, S. Jhunjhunwala, C. Benner, S. Heinz, E. Welinder,
R. Mansson, M. Sigvardsson, J. Hagman, C.A. Espinoza, J. Dut-
kowski, T. Ideker, C.K. Glass, C. Murre, A global network of
transcription factors, involving E2A, EBF1 and Foxo1, that
orchestrates B cell fate, Nat. Immunol. 11 (2010) 635–643.
[57] M.M. Del Real, E.V. Rothenberg, Architecture of a lymphomyeloid
developmental switch controlled by PU.1, Notch and Gata3,
Development 140 (2013) 1207–1219.
[58] Y. Arinobu, Reciprocal activation of GATA-1 and PU.1 marks initial
speciﬁcation of hematopoietic stem cells into myeloerythroid
and myelolymphoid lineages, Cell Stem Cell 1 (2007) 416–427.
[59] Y. Okuno, G. Huang, F. Rosenbauer, E.K. Evans, H.S. Radomska,
H. Iwasaki, K. Akashi, F. Moreau-Gachelin, Y. Li, P. Zhang, B.
Göttgens, D.G. Tenen, Potential autoregulation of transcription
factor PU.1 by an upstream regulatory element, Mol. Cell. Biol. 25
(2005) 2832–2845.
[60] M. Kobayashi, K. Nishikawa, M. Yamamoto, Hematopoietic regula-
tory domain of gata1 gene is positively regulated by GATA1 protein
in zebraﬁsh embryos, Development 128 (2001) 2341–2350.
[61] S.T. Chou, E. Khandros, L.C. Bailey, K.E. Nichols, C.R. Vakoc, Y. Yao,
Z. Huang, J.D. Crispino, R.C. Hardison, G.A. Blobel, M.J. Weiss, Graded
repression of PU.1/Sfpi1 gene transcription by GATA factors regulates
hematopoietic cell fate, Blood 114 (2009) 983–994.
[62] C. Nerlov, T. Graf, PU.1 induces myeloid lineage commitment in
multipotent hematopoietic progenitors, Genes Dev. 12 (1998)
2403–2412.
[63] S.N. Wontakal, X. Guo, C. Smith, T. MacCarthy, E.H. Bresnick, A.
Bergman, M.P. Snyder, S.M. Weissman, D. Zheng, A.I. Skoultchi, A
core erythroid transcriptional network is repressed by a master
regulator of myelo-lymphoid differentiation, Proc. Natl. Acad. Sci.
USA 109 (2012) 3832–3837.
[64] V. Chickarmane, T. Enver, C. Peterson, Computational modeling
of the hematopoietic erythroid–myeloid switch reveals insights
into cooperativity, priming, and irreversibility, PLoS Comput.
Biol. 5 (2009) e1000268.
[65] R. Monteiro, C. Pouget, R. Patient, The gata1/pu.1 lineage fate
paradigm varies between blood populations and is modulated by
tif1γ, EMBO J. 30 (2011) 1093–1103.
[66] D. Beck, J.A.I. Thoms, D. Perera, J. Schütte, A. Unnikrishnan,
K. Knezevic, S.J. Kinston, N.K. Wilson, T.A. O'Brien, B. Göttgens,
J.W.H. Wong, J.E. Pimanda, Genome-wide analysis of transcriptional
regulators in human HSPCs reveals a densely interconnected net-
work of coding and noncoding genes, Blood 122 (2013) e12–e22.
[67] N. Bonzanni, A. Garg, K.A. Feenstra, J. Schütte, S. Kinston, D.
Miranda-Saavedra, J. Heringa, I. Xenarios, B. Göttgens, Hard-wired
heterogeneity in blood stem cells revealed using a dynamic
regulatory network model, Bioinformatics 29 (2013) i80–i88.
[68] E. Diffner, D. Beck, E. Gudgin, J.A.I. Thoms, K. Knezevic, C. Pridans,
S. Foster, D. Goode, W.K. Lim, L. Boelen, K.H. Metzeler,
G. Micklem, S.K. Bohlander, C. Buske, A. Burnett, K. Ottersbach,
G.S. Vassiliou, J. Olivier, J.W.H. Wong, B. Göttgens, B.J. Huntly,
J.E. Pimanda, Activity of a heptad of transcription factors is
associated with stem cell programs and clinical outcome in acute
myeloid leukemia, Blood 121 (2013) 2289–2300.[69] G. Della Gatta, T. Palomero, A. Perez-Garcia, A. Ambesi-
Impiombato, M. Bansal, Z.W. Carpenter, K. De Keersmaecker,
X. Sole, L. Xu, E. Paietta, J. Racevskis, P.H. Wiernik, J.M.
Rowe, J.P. Meijerink, A. Califano, A.A. Ferrando, Reverse
engineering of TLX oncogenic transcriptional networks
identiﬁes RUNX1 as tumor suppressor in T-ALL, Nat. Med.
18 (2012) 436–440.
[70] M.L. De Marchis, M. Ballarino, B. Salvatori, M.C. Puzzolo, I.
Bozzoni, A. Fatica, A new molecular network comprising PU.1,
interferon regulatory factor proteins and miR-342 stimulates
ATRA-mediated granulocytic differentiation of acute promyelo-
cytic leukemia cells, Leuk.: Off. J. Leuk. Soc. Am. Leuk. Res. Fund
23 (2009) 856–862.
[71] R. Pal, M. Janz, D.L. Galson, M. Gries, S. Li, K. Jöhrens,
I. Anagnostopoulos, B. Dörken, M.Y. Mapara, L. Borghesi, L.
Kardava, G.D. Roodman, C. Milcarek, S. Lentzsch, C/EBPbeta
regulates transcription factors critical for proliferation and
survival of multiple myeloma cells, Blood 114 (2009) 3890–
3898.
[72] L. Brown, J.T. Cheng, Q. Chen, M.J. Siciliano, W. Crist, G. Buchanan,
R. Baer, Site-speciﬁc recombination of the tal-1 gene is a
common occurrence in human T cell leukemia, EMBO J. 9 (1990)
3343–3351.
[73] E. Clappier, The C-MYB locus is involved in chromosomal
translocation and genomic duplications in human T-cell acute
leukemia (T-ALL), the translocation deﬁning a new T-ALL subtype
in very young children, Blood 110 (2007) 1251–1261.
[74] I. Lahortiga, Duplication of the MYB oncogene in T cell
acute lymphoblastic leukemia, Nat. Genet. 39 (2007)
593–595.
[75] S.H. Oram, J.A.I. Thoms, C. Pridans, M.E. Janes, S.J. Kinston,
S. Anand, J.-R. Landry, R.B. Lock, P.-S. Jayaraman, B.J. Huntly,
J.E. Pimanda, B. Göttgens, A previously unrecognized promoter of
LMO2 forms part of a transcriptional regulatory circuit mediating
LMO2 expression in a subset of T-acute lymphoblastic leukaemia
patients, Oncogene 29 (2010) 5796–5808.
[76] F.J. Calero-Nieto, A. Joshi, N. Bonadies, S. Kinston, W.-I. Chan,
E. Gudgin, C. Pridans, J.-R. Landry, J. Kikuchi, B.J. Huntly,
B. Gottgens, HOX-mediated LMO2 expression in embryonic
mesoderm is recapitulated in acute leukaemias, Oncogene 32
(2013) 5471–5480.
[77] L.F. Peterson, D.-E. Zhang, The 8;21 translocation in leukemo-
genesis, Oncogene 23 (2004) 4255–4262.
[78] V. Gelmetti, J. Zhang, M. Fanelli, S. Minucci, P.G. Pelicci,
M.A. Lazar, Aberrant recruitment of the nuclear receptor
corepressor-histone deacetylase complex by the acute myeloid
leukemia fusion partner ETO, Mol. Cell. Biol. 18 (1998)
7185–7191.
[79] B. Lutterbach, J.J. Westendorf, B. Linggi, A. Patten, M. Moniwa,
J.R. Davie, K.D. Huynh, V.J. Bardwell, R.M. Lavinsky, M.G. Rosen-
feld, C. Glass, E. Seto, S.W. Hiebert, ETO, a target of t(8;21) in
acute leukemia, interacts with the N-CoR and mSin3 corepres-
sors, Molecular Cell. Biol. 18 (1998) 7176–7184.
[80] J. Wang, T. Hoshino, R.L. Redner, S. Kajigaya, J.M. Liu, ETO, fusion
partner in t(8;21) acute myeloid leukemia, represses transcrip-
tion by interaction with the human N-CoR/mSin3/HDAC1 com-
plex, Proc. Natl. Acad Sci. USA 95 (1998) 10860–10865.
[81] J.H.A. Martens, A. Mandoli, F. Simmer, B.-J. Wierenga, S. Saeed,
A.A. Singh, L. Altucci, E. Vellenga, H.G. Stunnenberg, E.R.G. FLI1,
binding sites demarcate targets for aberrant epigenetic regula-
tion by AML1-ETO in acute myeloid leukemia, Blood 120 (2012)
4038–4048.
[82] P. Liu, S.A. Tarlé, A. Hajra, D.F. Claxton, P. Marlton, M. Freedman,
M.J. Siciliano, F.S. Collins, Fusion between transcription factor CBF
beta/PEBP2 beta and a myosin heavy chain in acute myeloid
leukemia, Science 261 (1993) 1041–1044.
E X P E R I M E N T A L C E L L R E S E A R C H 3 2 9 ( 2 0 1 4 ) 2 5 5 – 2 6 4264[83] K. Shigesada, B. Van de Sluis, P.P. Liu, Mechanism of leukemo-
genesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11,
Oncogene 23 (2004) 4297–4307.
[84] B. Lutterbach, Y. Hou, K.L. Durst, S.W. Hiebert, The inv(16)
encodes an acute myeloid leukemia 1 transcriptional corepres-
sor, Proc. Natl. Acad. Sci. USA 96 (1999) 12822–12827.
[85] P. Shankaranarayanan, M.-A. Mendoza-Parra, M. Walia, L. Wang,
N. Li, L.M. Trindade, H. Gronemeyer, Single-tube linear DNA
ampliﬁcation (LinDA) for robust ChIP-seq, Nat. Methods 8 (2011)
565–567.[86] M. Adli, J. Zhu, B.E. Bernstein, Genome-wide chromatin maps
derived from limited numbers of hematopoietic progenitors, Nat.
Methods 7 (2010) 615–618.
[87] B. Mahata, X. Zhang, A.A. Kolodziejczyk, V. Proserpio, L. Haim-
Vilmovsky, A.E. Taylor, D. Hebenstreit, F.A. Dingler, V. Moignard,
B. Göttgens, W. Arlt, A.N.J. McKenzie, S.A. Teichmann, Single-cell
R.N.A. Sequencing Reveals T Helper Cells Synthesizing Steroids
De Novo to Contribute to Immune Homeostasis, Cell Rep. 7
(2014) 1130–1142.
